Demirci S, Turhan K, Ozsan N, Yalman D, Cakan A, Cok G, Cagirici U, Ozkok S
Department of Radiation Oncology, Ege University, Izmir, Turkey.
Thorac Cardiovasc Surg. 2011 Apr;59(3):153-7. doi: 10.1055/s-0030-1250657. Epub 2011 Apr 8.
Aim of the study was to identify and evaluate the prognostic efficacy of standard clinicopathological factors of thymic epithelial tumors (TETs) for treatment-related outcomes.
All patients treated between 1993-2008 at Ege University Faculty of Medicine Departments of Radiation Oncology and Thoracic Surgery were reviewed retrospectively.
Forty-seven patients with a median age of 51 (range: 24-72) were identified. Complete resection was performed in 23 (51.1%), incomplete resection with microscopic residues in 17 (37.8%), subtotal resection with gross residues in 2 (4.4%) and biopsy in 5 (11.1%) patients. Radiotherapy was administered to 39 (83%) patients. Median follow-up duration was 51 months (range: 3-168 months). Five-year local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) rates were 93%, 90% and 85% for thymoma and 80%, 66% and 72% for thymic carcinoma patients, respectively. In multivariate analysis, the extent of resection was the only significant prognostic factor for OS (P = 0.001).
The most important prognostic factor for overall survival was the extent of resection. Further studies with larger numbers of patients are required to confirm the prognostic factors and to obtain a better understanding of the biological behavior of TETs.
本研究旨在识别和评估胸腺上皮肿瘤(TETs)的标准临床病理因素对治疗相关结局的预后效果。
回顾性分析了1993年至2008年间在伊兹密尔埃杰大学医学院放射肿瘤学和胸外科接受治疗的所有患者。
共纳入47例患者,中位年龄51岁(范围:24 - 72岁)。23例(51.1%)患者行根治性切除,17例(37.8%)患者行显微镜下有残留的不完全切除,2例(4.4%)患者行肉眼有残留的次全切除,5例(11.1%)患者行活检。39例(83%)患者接受了放疗。中位随访时间为51个月(范围:3 - 168个月)。胸腺瘤患者的5年局部无复发生存率(LRFS)、无病生存率(DFS)和总生存率(OS)分别为93%、90%和85%,胸腺癌患者分别为80%、66%和72%。多因素分析显示,切除范围是OS的唯一显著预后因素(P = 0.001)。
总生存的最重要预后因素是切除范围。需要更多患者的进一步研究来证实预后因素,并更好地了解TETs的生物学行为。